Ophthotech partners with University of Florida, Penn for gene therapy development

Ophthotech has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania to develop and commercialize a novel adeno-associated virus gene therapy product to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa, the company announced in a press release.
In addition, Ophthotech and Penn have also entered into a master sponsored research agreement to conduct preclinical and natural history studies, the release said.
Rhodopsin-mediated autosomal dominant retinitis pigmentosa, an orphan monogenic disease that

Full Story →